Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Issue 2 (30th March 2015)

• Record Type: Journal Article
• Authors: Soares‐da‐Silva, Patrício; Pires, Nuno; Bonifácio, Maria João; Loureiro, Ana I.; Palma, Nuno; Wright, Lyndon C.
• Is Part Of: Pharmacology research & perspectives. Volume 3:Issue 2(2015:Apr.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2015-03-30
• Subjects: Carbamazepine -- eslicarbazepine -- fast inactivation -- lacosamide -- oxcarbazepine -- slow inactivation -- voltage‐gated sodium channel; Pharmacology -- Periodicals; Drug development -- Periodicals; 615.105
• DOI: 10.1002/prp2.124
• Languages: English
• ISSNs: 2052-1707

Abstract

Abstract: Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health Canada as an adjunctive therapy in adults with partial‐onset seizures (POS). In humans and in relevant animal laboratory species, ESL undergoes extensive first pass hydrolysis to its major active metabolite eslicarbazepine that represents ~95% of circulating active moieties. ESL and eslicarbazepine showed anticonvulsant activity in animal models. ESL may not only suppress seizure activity but may also inhibit the generation of a hyperexcitable network. Data reviewed here suggest that ESL and eslicarbazepine demonstrated the following in animal models: (1) the selectivity of interaction with the inactive state of the voltage‐gated sodium channel (VGSC), (2) reduction in VGSC availability through enhancement of slow inactivation, instead of alteration of fast inactivation of VGSC, (3) the failure to cause a paradoxical upregulation of persistent Na + current ( I NaP ), and (4) the reduction in firing frequencies of excitatory neurons in dissociated hippocampal cells from patients with epilepsy who were pharmacoresistant to carbamazepine (CBZ). In addition, eslicarbazepine effectively inhibited high‐ and low‐affinity hCaV 3.2 inward currents with greater affinity than CBZ. These preclinical findings may suggest the potential for antiepileptogenic effects; furthermore, the lack of effect upon KV 7.2 outward currents may translate into a reduced potential for eslicarbazepine to facilitate repetitive firing. Abstract : e00124